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Rheumatic fever and 
rheumatic heart disease:  
Where are we now in South Africa?
The ASAP programme collaborates with other similar pro-
grammes of the World Heart Federation (WHF) globally, and has 
also been adopted by the Inter Academy Medical Panel as one of 
six global programmes.
Following the Drakensberg meeting, there has been renewed 
interest among cardiologists, other medical and public health 
professionals, the community and most importantly, government 
to be proactive in combating RF and RHD.
Scale of RF/RHD
Over the last 150 years the developed world has experienced a 
dramatic decline in the incidence and prevalence of RF/RHD 
through improved living conditions and the widespread use of 
penicillin for the treatment of group A beta haemolytic strepto-
coccal pharyngitis.  However, developing countries, which account 
for 80% of the world’s population, continue to face unacceptably 
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ASAP PROGRAMME
INTRODUCTION                                                              
In October 2005, the Pan African Society of Cardiology convened 
the fi rst All Africa Workshop on Rheumatic Fever (RF) and 
Rheumatic Heart Disease (RHD) in Drakensberg, South Africa. 
The event concluded with the adoption of the Drakensberg 
Declaration, a statement proposing an action plan targeting RF 
and RHD in Africa.(1)  
Named the Awareness Surveillance Advocacy Prevention (ASAP) 
programme it emphasises four key areas, namely awareness, 
surveillance, advocacy, and prevention.  
Strategy of the ASAP programme in RF and RHD: 
raise public and health professional awareness 
establish surveillance systems 
advocacy for increased resources for treatment
promoting the prevention of RF/RHD in African nations 
■
■
■
■
South Africa continues to face unacceptably high rates of 
rheumatic fever (RF) and rheumatic heart disease (RHD), 
despite readily available and inexpensive preventive measures. 
However, in the past several years, key players in South 
Africa’s healthcare and political realms in addition to key 
players from many African nations have come together to 
acknowledge the persistent health burden attributable to 
RF/RHD and have agreed to a pledge of action to reduce it. 
The plan of action is a comprehensive RF/RHD prevention 
and treatment programme known as ASAP.  The ASAP 
programme targets efforts to raise Awareness, establish 
Surveillance systems, Advocate for increased resources for 
treatment, and to promote Prevention strategies. South 
Africa currently has a demonstration site where activities in 
all of these key areas are currently underway.  Efforts in the 
area of surveillance include a RHD prevalence study that 
aims to screen 4 000 school-aged children through the use of 
a mobile echo-surveillance unit.  In addition to local efforts, 
South Africa will join an international initiative to create a 
global RHD registry that will aid in all aspects of prevention 
and treatment to further reduce the burden of disease 
attributable to RF/RHD. SAHeart 2009; 6:20-23
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high rates of RF/RHD, making it the most common cardiovascular 
disease affecting children and young adults in the world.(2)
Together, RF & RHD affect about 15.6 million people worldwide, 
2.4 million of whom are children between fi ve and fourteen years 
old in developing countries.(3) Sub-Saharan Africa and South Central 
Asia account for the majority of cases. Almost 500 000 new cases 
are declared every year. RF/RHD leads to an estimated 
350 000 deaths annually, and hundreds of thousands of survivors 
are left disabled without access to the expensive medical and 
surgical care that the disease requires. 
It is estimated that 0.3 - 3% of those with untreated group A beta 
haemolytic streptococcal infection progress to develop acute 
rheumatic fever ; and such infection may often be asymptomatic. 
Approximately 40 - 60% of episodes of RF result in RHD.
Africa, which contains 10% of the world’s population, has a 
disproportionately high share of people living with RF/RHD. In 
2002, of the 2.4 million children with RF/RHD living in developing 
countries, nearly half (>1 million) live in sub-Saharan Africa, making 
the continent the major hotspot of RF/RHD.(3)  RF is a disease of 
poverty; it is particularly rampant in low-income, overcrowded 
communities with poor housing conditions, poor nutrition and 
inadequate health services. A neglected “strep” throat (sore 
throat caused by streptococcal bacteria) can lead to repeated 
episodes of RF affecting mainly the large joints (arthritis) and the 
heart (carditis), causing chronic heart valve damage (RHD) which 
may necessitate expensive heart valve surgery. The condition is 
usually fatal if damaged heart valves are not repaired or replaced by 
major open-heart surgery.
RF and RHD are among the commonest causes of cardiovascular 
morbidity and mortality in developing countries. RHD is the second 
common cause of heart failure (after hypertension) in Africans and 
the commonest indication for cardiac surgery in tropical Africa, 
accounting for nearly 60% of open heart surgery.(4) 
There is a paucity of information on the prevalence of RHD in 
South Africa. Two previous studies of the prevalence of RHD in 
South Africa used clinical auscultation (not echocardiography) to 
screen for RHD.(5,6) Both studies provided an estimate of 6.9/1 000 
school children, which may however, be an underestimate of the 
prevalence of RHD among children because of the low sensitivity 
of the method of screening used (i.e. clinical examination) and 
probable absence from school of more sick children with RHD. 
Clearly, alternative methods of screening for RF/RHD such as 
mobile echocardiography would provide a more accurate estimate 
of the prevalence of RF/RHD in the general population.  A systematic 
review of prevalence studies found exceptionally high rates of 
RHD in sub-Saharan Africa, with the highest level in Kinshasa, DRC 
at 14/1000 school-aged children.(7)  Similar high prevalence rates 
have been found in Cairo, Egypt (5.1/1 000) and Addis Ababa, 
Ethiopia (6.4/1 000).(8)  More recently, an echocardiographic-based 
study in Mozambique reported rates of 30/1 000.(9)
To date there have been no studies of the incidence of RF/RHD in 
Africa. Anecdotal information suggests that the incidence of RF 
remains quite high in South Africa and that RHD is still the leading 
cause of acquired heart disease in children and young adults.(10) In a 
2002 report from a pediatric cardiology conference, a consensus 
opinion was that South Africa was in the midst of an RF epidemic(11) 
despite national guidelines and recommendations for antibiotic 
prevention of the disease.(12) Furthermore, there appears to be 
underreporting of RF cases by health care professionals, and poor 
administration of the RF notifi cation system. A detailed analysis of 
the number of RF cases reported at hospital, municipal and provincial 
level for a 5-year period suggested underreporting by health care 
professionals and poor administration of the notifi cation system.(13)
Prevention / therapeutic options
RF/RHD is a disease of poverty, of children, unrelated to lifestyle 
and killing young people in the prime productive years of their lives. 
Sadly, it is almost entirely preventable using demonstrated strategies 
that are cheap and cost-effective. Prevention efforts are most 
effective when supported by a comprehensive programme that 
includes health education for parents, children, teachers and 
health care providers, routine screening, availability of penicillin 
and maintenance of a disease registry to manage known cases. 
Moreover, primary and secondary prevention programmes can 
be implemented through the existing health care services without 
major additional costs. 
In 1997, the South African Department of Health (DOH) released 
a set of national guidelines on the primary prevention and 
prophylaxis of RF and RHD. The guidelines were intended to 
facilitate a comprehensive programme for the primary and 
secondary prevention of RF.  Targeting health workers at the primary 
care level, they cover interventions addressing education, living 
conditions, diagnosis, treatment, referral, notifi cation, and follow-
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up.  An evaluation of adherence to the guidelines indicated that in 
addition to physician awareness and compliance with the national 
guideline being unsatisfactory, the method for case detection of RF 
was unclear.(12) A revision of the guidelines has recently been 
submitted to the department of health and is awaiting approval.
Many fi rst episodes of RF can be prevented by a simple injection of 
penicillin for strep sore throat (primary prevention).(10) Even if 
the fi rst episode of RF is not prevented, further episodes (which 
almost always lead to RHD) are entirely preventable through 
secondary prevention. Secondary prevention requires the delivery 
of regular penicillin injections to prevent further RF and worsening 
RHD, and is the mainstay of controlling RF/RHD.(14) At the end of 
the spectrum, is the need for surgical intervention to repair scarred 
valves. In 2000, the average cost of operative treatment for RHD 
in Africa was around US$5 000; in low income countries of 
sub-Saharan Africa with a GNP per capita of less than US$500, 
such as Ghana, increasing health expenditure to address this cost 
would adversely affect poverty reduction strategies.(4)  Unfortunately, 
the downscaling of quotas for operations over the years makes it 
diffi cult to establish the true extent of the need for this procedure 
in South Africa.  
Vaccines to prevent rheumatic fever?
The development of vaccines would represent the most ideal 
strategy of control to prevent group A streptococcal–related 
disease. Despite attempts dating back for more than 50 years, 
vaccination has hitherto proved impossible.  Recently, concentration 
of efforts has been on the organism’s M Protein epitopes, the 
diversity of which need to be elucidated: a study is currently 
underway to establish the molecular epidemiology of the bacteria 
in Cape Town. It is thus conceivable that South Africa would play 
a pivotal part in clinical trials of new vaccines for group A 
streptococcus in the future.
 
Lack of attention 
There has been a dearth of activity related to RHD over the past 
two decades in Africa and elsewhere as the attention of cardio-
logists has tended to focus on ischaemic heart disease, while the 
attention of public health practitioners has tended to focus on 
HIV, AIDS and TB. Hypertension, and its cardiac and cerebro-
vascular sequelae probably represent the major burden of 
cardiovascular disease in Africa, but RF/RHD is still the major cause 
of acquired heart disease in Africa and indeed the world.(15) It is 
amongst the top three causes of heart failure in sub-Saharan 
Africa.(16)
CURRENT INITIATIVES                                                   
Launch of South African demonstration site
In South Africa, the ASAP Programme has designated the 
Vanguard Community in Cape Town as its demonstration site. 
To date, the ASAP team has been conducting awareness-
raising presentations amongst parents, teachers and community 
members. In addition, we have held seminars for health profes-
sionals to enable them to recognise and diagnose streptococcal 
sore throat, and make valid management decisions.  
Recently, portable echocardiography had been applied in landmark 
papers to assess the incidence of RHD in Cambodia, Mozambique(9) 
and Tonga.(17) It is well known that Doppler echocardiography is 
highly sensitive in demonstrating valvular regurgitation.(18) Using 
this method, the highest incidence of RHD hitherto has been 
demonstrated in Tonga.(17) In addition, their fi ndings show that 
auscultatory fi ndings alone would have missed more than half of 
the pathological lesions as later defi ned by echocardiography.  This 
obviously has great implications for a screening programme based 
in an area of high-prevalence, with little or no resources. 
The recent acquisition of a customised mobile echo-surveillance 
unit has enabled the launch of the surveillance component of the 
programme, where approximately 4 000 school-aged participants 
will be screened for the prevalence of RHD.  This involves a 
comprehensive assessment with particular attention paid to skin 
lesions, auscultation by a pediatric cardiologist followed by a full 
echocardiogram. This dataset forms part of a prospective study 
appraising echocardiography as a screening tool for RHD in 
developing countries.  In addition, participants will be screened for 
skin conditions and referred to the appropriate clinic for follow-up. 
The skin assessment is also of interest following work from 
Australia looking at relative incidences of pharyngitis verses 
pyoderma in high-prevalence communities.(19) All echocardiograms 
will be reviewed by a pediatric cardiologist and all cases detected 
will be reviewed by partners at Red Cross Hospital. It is anticipated 
that the results from this study, in addition to providing a comparison 
between auscultation and echocardiography in our setting, will add 
to the growing body of literature establishing the world-wide 
prevalence of RHD.  
Establishment of a global registry for RHD
In 1972, the WHO launched a register-based programme to 
combat RF/RHD. Subsequently the programme was expanded and 
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by 1990, registers had been established in 16 countries with over 
one million school-going children screened yielding over 3 000 
cases of RHD.  However the declining rate of RHD in developed 
countries brought this initiative to a halt and in 2001, the 
WHO ceased its funding to this global programme.(20) Experience 
elsewhere has provided evidence of registers realising notable 
successes in reducing RF recurrence.(21) Thus, the absence of 
contemporary, systematically collected data is a gap that needs to 
be bridged in order to effectively treat patients with RHD in 
developing countries, where the rate of RF/RHD has not mirrored 
the decline in developed countries.  
A global registry was launched at the South African Heart 
Association Congress 2008 and will be an international collabora-
tion within the auspices of the WHF and ASAP. The purpose of 
this registry is to collect data on demographic and clinical profi les 
of patients with RHD in low and middle-income countries. It is 
also important to ascertain whether differences in patient 
characteristics in communities have clinical relevance especially as 
regards outcomes, since this may impact upon management 
strategies within different communities and age groups.  A registry 
should also highlight defi ciencies in service delivery to the most at 
risk patients and therefore guide in the initiation of more specifi c 
interventions. McDonald et al have suggested priority-based 
guidelines to evaluate and manage patients with severe, moderate 
and mild disease.(21) In further assessment, specifi c performance 
indicators can then be reviewed in line with these guidelines.(22) 
The computerised register of cases of RF and RHD will be used to 
improve treatment adherence in order to prevent recurrent RF 
and the development of RHD necessitating surgery.  In addition, 
the registry will serve as an epidemiological tool for gathering 
detailed echocardiography information for the purpose of research, 
compiling reference ranges and guiding the development of 
protocols and guidelines to improve secondary prophylaxis 
adherence.(23)
It is envisaged that the model of surveillance and prevention of 
RF/RHD will be successfully established, and can be rolled out at 
country level in order to prevent RF among children and thus 
avoid RHD and cardiac surgery.  Through efforts such as ASAP as 
well as implementation of the National Department of Health 
guidelines for the prevention and treatment of RF/RHD, it is certainly 
feasible that both RF and RHD could be eradicated from South 
Africa within one or two generations, mimicking the achievements 
made recently in Cuba.(24)  
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